Indication:
This product is indicated for the treatment of:
-Adult patients and pediatric patients aged 2 years and older with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase.
-Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase or accelerated phase who are resistant or intolerant to prior therapies (including imatinib), as well as pediatric patients aged 2 years and older with Ph+ CML in the chronic phase.